De novo design of miniproteins targeting GPCRs
2d ago· 1 min readNews
Source
Design breakthrough: de novo miniproteins targeting GPCRs, harnessing advanced computational methods and high-throughput screening for precise interaction. PMID:42168559, Nature 2026, @Nature #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
You might also wanna read
University of Copenhagen Seeks Two Tenure-Track Faculty in De Novo Protein Design
The Novo Nordisk Foundation Center for Protein Design at the University of Copenhagen is hiring two tenure-track group leaders (Assistant or

Study identifies MD-1 as endogenous agonist for orphan receptor GPRC5B, linking macrophages to adipocyte signaling
This article describes research identifying MD-1 as an endogenous agonist for the orphan G protein-coupled receptor GPRC5B. Using a virion-b
Derek Lowe on "Peptides"
science.org·2mo ago
Reflections on 2024 Bio-ML Predictions: Generative Chemistry and Molecular Dynamics Challenges
The article reflects on the author's 2024 predictions about bio-ML (biological machine learning) from a 2026 perspective, focusing on genera

AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
The article discusses recent advancements in AI-driven drug discovery, highlighting two key developments: 1) Analytica 2026, an event focuse
Harmonic Discovery: AI-powered platform for precision drug design launches on Product Hunt
Harmonic Discovery is a biotech platform that uses machine learning and generative chemistry to design safer, more effective medicines. The

Comments
Sign in to join the conversation.
No comments yet. Be the first.